Compare RYAM & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAM | OCGN |
|---|---|---|
| Founded | 1926 | 2013 |
| Country | United States | United States |
| Employees | 2325 | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.4M | 474.8M |
| IPO Year | 2014 | 2014 |
| Metric | RYAM | OCGN |
|---|---|---|
| Price | $8.23 | $0.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $14.00 | $9.75 |
| AVG Volume (30 Days) | 660.6K | ★ 6.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,466,397,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.22 | $1,718.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.38 | $1.01 |
| 52 Week High | $11.85 | $2.73 |
| Indicator | RYAM | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 32.92 |
| Support Level | $8.18 | N/A |
| Resistance Level | $8.81 | $1.49 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 17.54 | 16.28 |
Rayonier Advanced Materials Inc engaged in the production and sale of high-purity cellulose and other cellulose-based materials derived from renewable wood fiber. The company operates through five segments: Cellulose Specialties, which produces purified cellulose used in products such as filters, pharmaceuticals, food additives and electronics; Biomaterials, which produces products including biofuels, lignosulfonates and other bio-based chemicals; Cellulose Commodities, which manufactures absorbent and viscose pulp used in textiles and hygiene products; Paperboard, which produces coated paperboard used for packaging and printing applications; and High-Yield Pulp, which produces pulp used in paperboard, packaging and printing paper products.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").